Despite the development of numerous novel antiepileptic drugs (AEDs) in recent years, several unmet clinical needs remain, including resistance to AEDs in about 30 % of patients with epilepsy, adverse effects of AEDs that can reduce quality of life, and the lack of treatments that can prevent development of epilepsy in patients at risk. Animal models of seizures and epilepsy have been instrumental in the discovery and preclinical development of novel AEDs, but obviously the previously used models have failed to identify drugs that address unmet medical needs. Thus, we urgently need fresh ideas for improving preclinical AED development. In this review, a number of promising models will be described, including the use of simple vertebrates such as zebrafi sh ( Danio rerio ), large animal models such as the dog and newly characterized rodent models of pharmacoresistant epilepsy. While these strategies, like any animal model approach also have their limitations, they offer hope that new more effective AEDs will be identifi ed in the coming years.
Introduction
Rodent models of seizures and epilepsy have played a fundamental role in advancing our understanding of basic mechanisms underlying ictogenesis and epileptogenesis. They have also been instrumental in the discovery and preclinical development of novel antiepileptic drugs (AEDs) [ 12 ] . Indeed, animal models with a similarly high predictive value do not exist for other neurological disorders, such as bipolar disease or migraine [ 62 ] . Despite the availability of predictive rodent models, at least 30 % of epilepsy patients are not controlled by currently available AEDs. One reason is that, with few exceptions, most AED candidates were identifi ed in simple evoked seizure models in otherwise healthy rodents such as the maximal electroshock seizure (MES) or acute pentylenetetrazole (PTZ; metrazol) tests [ 48 ] . In these traditional models, in use since the 1940s, successful AED treatments suppress acute seizure events, but effects on drugresistant seizure events or chronic spontaneous seizures are not routinely evaluated. Thus, we urgently need fresh ideas for improving preclinical AED development. Here, a number of promising models will be described, including the use of simple vertebrates such as zebrafi sh ( Danio rerio ), large animal models such as the dog and newly characterized rodent models of pharmacoresistant epilepsy. We will not discuss in vitro brain slice models or neurons derived from patients using induced pluripotent stem cell technology, because the network complexity of the brain and its alterations by seizure activity are diffi cult to recapitulate in the dish.
Zebrafi sh-Based Approaches to Epilepsy and Drug Discovery
Traditionally used as a model organism to study vertebrate development and embryogenesis, zebrafi sh only recently emerged as an important model for epilepsy research [ 5 , 17 , 27 , 29 , 53 , 65 , 70 ] . The rapid ex vivo development, genetic tractability and transparency of larval zebrafi sh make them ideally suited to these types of studies ( Fig. 23.1 ). Because zebrafi sh are vertebrates with a fairly complex nervous system [ 2 , 21 , 61 ] recording electroencephalographic activity is also possible [ 7 ] , and with exposure to standard convulsant manipulations (e.g., PTZ, pilocarpine, 4-aminopyridine, heat) abnormal electrical discharge with brief high-frequency small amplitude (interictal-like) and longer duration, complex multi-spike large amplitude (ictal-like) events can be readily observed. Sophisticated imaging approaches, taking advantage of the transparency of larval zebrafi sh and genetic modifi cation to express calcium or bioluminescence indicators, provide additional evidence that central nervous system (CNS)-generated seizure-like activity is robust in response to PTZ. This is an important advantage of zebrafi sh as a model organism for epilepsy research as CNS-generated abnormal electrical events are often considered a hallmark feature of this disease. In the original description of the acute PTZ seizure model in wild-type zebrafi sh at 6 or 7 days post-fertilization (dpf), Baraban et al. [ 5 ] provided a framework for characterizing epilepsy in zebrafi sh: (i) evidence for seizure-induced gene ( c-Fos ) expression, (ii) a scoring system for seizure-like behaviours, (iii) electrophysiological examples of abnormal electrographic burst discharge and (iv) sensitivity to common AEDs (valproate, ethosuximide, carbamazepine, phenytoin, phenobarbital and diazepam). As expected from similar PTZ testing in rodents [ 71 ] , valproate and diazepam were the most effective at inhibiting electrographic seizure events with approximate ED 50 s of 1 mM and 5 μM, respectively. Using this same model, Berghmans et al. [ 11 ] extended this dataset to include 14 standard AEDs. These follow-up experiments used an assay where wild-type larvae were "incubated" in a test compound for 24 h prior to acute PTZ administration and monitoring of seizure-like behaviour exclusively in a locomotion-based tracking assay. These studies confi rmed the results of Baraban et al. [ 5 ] but also highlight the limitations of a behaviour-only assay as two drugs that failed to alter electrographic burst discharge amplitude (ethosuximide and carbamazepine) were identifi ed as "anticonvulsant" as measured by a reduction in swim activity. A likely explanation is that overnight exposure to these AEDs was either toxic or sedative to developing zebrafi sh, as both possibilities would appear as suppressed locomotion in motion-based tracking assay. More recently, Afrikanova et al. [ 1 ] revisited this overnight exposure-PTZ challenge assay and evaluated a similar list of 13 AEDs using a combination of locomotion tracking followed by electrophysiology on agar-immobilized larvae. These latter studies aligned most closely with the original PTZ fi ndings, identifying valproate and diazepam, while also showing that ethosuximide altered burst frequency but not amplitude. Maximum-tolerated drug concentrations were studied in both papers highlighting an additional advantage of the zebrafish platform for simultaneous in vivo evaluation of drug toxicities e.g., one of the primary reasons that most compounds identifi ed in preclinical trials ultimately fail to reach the clinic. In a recent paper by Baxendale et al. [ 10 ] also using PTZ, a high-throughput screen of a ~2,000 bioactive small molecule library was reported. These studies used a fi rst-pass assay based on increased c-Fos mRNA expression (as measured by in wholemount situ hybridization) following PTZ exposure at two dpf and a secondary locomotion-based assay at four dpf for additional concentration-response studies. Unfortunately, it is unclear whether the 46 compounds identifi ed using this approach are antiepileptic as previous studies indicate the earliest possible developmental stage where confi rmed electrographic seizures could be observed in zebrafi sh larvae is three dpf [ 6 , 27 ] . Before this age, larvae are still in chorion and do not swim freely. Furthermore, these non-physiological assays should be interpreted with caution as the Baxendale et al. [ 10 ] study identifi ed several candidate compounds with known neurotoxicity profi les e.g., lindane, rotenonic acid, deguelin, endrin and propanil. Although seizures can be easily induced, drug discovery using acute seizure models, even in zebrafi sh, are prone to the same limitations as in rodents. Namely, these approaches use healthy animals, the seizure-events are acute and evoked using potentially non-physiological stimuli such as a stimulation electrode or convulsants, and most importantly they do not model spontaneously occurring seizure events. Zebrafi sh diverged from humans roughly 450 million years ago but recent genome sequencing revealed that the similarity between the zebrafi sh and human genome is ~70 % [ 28 ] . This fact, coupled with the fecundity of adult zebrafi sh (producing 100-200 offspring per week from a single adult breeding pair), the permeability of larvae to drugs placed in the bathing media, and ability to thrive in volumes as small as 100 μl make zebrafi sh an attractive model for a drug discovery program targeted to genetic forms of epilepsy. In the Baraban laboratory, we have focused on zebrafish designed to mimic monogenic epilepsy disorders of childhood as they offer the advantages of spontaneous seizure activity and a genetic basis mimicking the human condition. In this approach, one can model specifi c forms of pediatric epilepsy -Type I Lissencephaly ( Lis1 ), Angelman syndrome ( Ube3A ), Tuberous Sclerosis Complex ( Tsc ) or Dravet syndrome for example ( Scn1a ) -then design drug screening programs targeted to that patient population. In some cases these are stable mutations carried in the zebrafi sh germline, where other models involve acute antisense knockdown of gene expression in immature zebrafi sh. Thus, a form of "personalized medicine" aimed at identifying new therapeutic options for relatively rare, but catastrophic, forms of epilepsy. Our recent studies are based on a two-stage screening process. First, zebrafi sh mutants are placed in individual wells and behaviour (locomotion) is tracked using a 96-well format. Once a baseline level of spontaneous seizure activity is established a test compound is added, and then a second locomotion assay is performed to evaluate the effect on seizure behaviour (with distance travelled and mean velocity of swim movement used as surrogate markers) [ 5 , 16 ] . As freely behaving larvae can simultaneously be observed for heart rate, edoema or touchsensitivity, in vivo toxicity is also determined with this strategy. Using a 96-well format it is relatively easy to power this research for statistical analysis and multiple drug concentrations can be assessed in a given plate. The same fi sh can subsequently be used for electrophysiological analysis, which allows a determination of "false positives" in the locomotion assay that are lethal, sedative or paralyzing. With even a modest zebrafi sh facility, this approach can easily be used to screen 20-50 drugs per week. The disadvantage of this strategy is that it is not well-suited to acquired forms of epilepsy that develop more slowly over time or in the adult nervous system, or compounds that are not easily dissolved in embryo media. It is also diffi cult to directly translate concentrations that are effective via bath application in larval zebrafi sh to those that may be useful clinically in humans.
Rodent Models of Pharmacoresistant Seizures
The concept of developing rodent seizure or epilepsy models that do not respond to clinically approved AEDs and then using such models for the discovery of novel more effective AEDs is not new but, to our knowledge, was fi rst proposed by Löscher in 1986 [ 38 ] . Since then, several models of pharmacoresistant seizures have been developed, including the phenytoin-resistant kindled rat [ 40 ] , the lamotrigine-resistant kindled rat [ 68 ] , and the phenobarbital-resistant epileptic rat [ 14 ] . In all these models, resistance to one AED extends to other AEDs (cf., [ 49 ] ), thus fulfi lling the criterion of pharmacoresistant epilepsy [ 32 ] . By using two of these models, Löscher and colleagues described several factors that differentiated AED-resistant from AED-responsive rats, including the extent of neurodegeneration in the hippocampus, genetic factors, AED target alterations, alterations in drug effl ux transporters, and intrinsic severity of the epilepsy as a determinant of AED refractoriness [ 49 ] . Similar factors have been described for AED-resistant human epilepsy, so that the rat models obviously refl ect clinically important mechanisms of refractoriness. The next logical step was to use such models for new treatment discovery. One example here is that inhibiting the drug effl ux transporter P-glycoprotein (Pgp), which is increased at the blood-brain barrier of AED-resistant rats, counteracted resistance to phenobarbital in epileptic rats [ 15 ] . The increased Pgp functionality in epileptic rats can be visualized in vivo by positron emission tomography [ 4 ] . By using Pgp imaging, Feldmann et al. [ 19 ] demonstrated that about 40 % of AED-resistant patients exhibit increased brain functionality of Pgp and could potentially benefi t from Pgp inhibition. This example illustrates that chronic rodent models of pharmacoresistant seizures are helpful to discover new strategies for treatment of medically intractable epilepsy. The disadvantage of the described chronic epilepsy models is that they are not suited for large-scale testing of novel compounds but rather for evaluation of selected treatment strategies as illustrated by the example of Pgp inhibition. Kindling models such as the phenytoin-resistant kindled rat [ 40 ] or the lamotrigine-resistant kindled rat [ 68 ] have the advantage that seizures can be induced at will, so that chronic drug administration is not needed, whereas models with spontaneous recurrent seizures (SRS) such as the phenobarbital-resistant epileptic rat [ 14 ] necessitate continuous (24/7) EEG/video recording for assessing drug effi cacy. When testing drug effects on SRS in such rat models, the rapid elimination of most drugs, including AEDs, in rats (Table 23 .1 ) necessitates the use of an adequate dosing regimen during prolonged drug administration to Data are from previous reviews of Löscher [ 44 , 46 ] and have been revised and updated for the present study. Note that rats and dogs eliminate most AEDs more rapidly than humans, which has to be considered when using such drugs for chronic studies in experimental animals DMD desmethyldiazepam, MHD monohydroxy derivative, PB phenobarbital, ? indicates that no published data were found a Active metabolites; b shortens on continuing exposure to the drug (because of enzyme induction); c non-linear kinetics (half-life increases with dose); d duration of action independent of half-life because of irreversible inhibition of GABA degradation avoid false negative results [ 46 ] . The same is true when administering potential antiepileptogenic drugs in the latent period following epileptogenic brain insults in rats [ 46 ] . Mice developing SRS after intrahippocampal injection of kainate have been proposed as a model of pharmacoresistant seizures; these mice have the advantage that the frequency of SRS is so high that drug effi cacy can be determined after single dose administration [ 54 , 66 ] . However, as yet this model has only rarely been used for investigating the antiepileptic effi cacy of novel compounds [ 54 ] .
Based on the logistical problems associated with drug testing in chronic models, models such as the zebrafi sh or acute rodent seizure models are indispensable when testing large numbers of investigational compounds before evaluating the most interesting compounds in chronic models. One of these acute seizure models, the 6-Hz model of partial seizures in mice, was initially proposed to provide a useful model of therapyresistant limbic seizures [ 9 ] , but more recent studies have not confi rmed this idea [ 49 ] . Rather, the 6-Hz model is a valuable part of a preclinical test battery to further differentiate compounds. Also, a more recent genetic mouse model of Dravet syndrome, in which clinical symptoms of this syndrome occur after Scn1a heterozygous knockout, may be an interesting possibility for testing drugs or drug combinations for treatment of as yet pharmacoresistant types of seizures [ 59 , 60 ] . Furthermore, a zebrafi sh Scn1a mutant, such as the one recently described by the Baraban laboratory [ 8 ] would be an effi cient fi rst pass highthroughput approach to identify potential candidate compounds that can be further investigated in chronic rodent models of pharmacoresistant seizures.
Naturally Occurring Epilepsy in Dogs as a Translational Model
The dog is an important large animal model in various fi elds of biomedical research and fi lls a crucial step in the translation of basic research to new treatment regimens. For instance, because of the relative large body size of dogs and many similarities in physiology and pharmacology between dogs and humans, scaling doses from dogs to humans is much easier than using rodents in selecting doses for clinical trials in humans. To our knowledge, Löscher et al. [ 37 ] were the fi rst to propose naturally occurring canine epilepsy as a translational model of human epilepsy. The prevalence and phenomenology of epilepsy in dogs are very similar to human epilepsy. Indeed, epilepsy is the most common chronic neurological disease in dogs, affecting about 0.6-1 % of the dog population [ 64 , 69 ] . Furthermore, causes of canine epilepsy are similar to those in humans ( Fig. 23.2 ) except that cerebrovascular disease does not play any signifi cant role, because it is rare in dogs [ 69 ] . About 50 % of dogs with partial and generalized convulsive seizures are not controlled by treatment with AEDs, so that epileptic dogs have been proposed as a valuable model of pharmacoresistant epilepsy that can be used to unravel mechanisms of resistance and evaluate new strategies for treatment [ 44 , 64 ] . However, clinical trials on new AEDs in epileptic dogs are as laborious and time-consuming as clinal trials in human patients, necessitating randomized trial designs in which the new drug is compared with either placebo or a standard comparator [ 57 , 58 ] . Recently, different treatments, including AEDs, vagal stimulation, and ketogenic diet were compared with placebo in epileptic dogs, and an unexpectedly high placebo rate was found, which was similar to that known from controlled clinical trials in humans with epilepsy [ 57 , 58 ] . In contrast to humans, the placebo effect has been largely disregarded in veterinary medicine. In humans, a placebo response seems to require a recognition by the patient of the intent of treatment efforts. Because it is generally presumed that animals lack certain cognitive capacities, e.g. the ability to comprehend the intent of the veterinarian's manipulations, the power of suggestion, and expectations of recovery and healing, the existence of a placebo effect in animals seems counterintuitive [ 55 ] . However, in veterinary studies, the placebo response may be a result of expectations of the pet owner regarding treatment in studies as those conducted by Munana et al. [ 57 , 58 ] in epileptic dogs, where the owners are responsible for administration of treatment and outcome measures (i.e., seizure frequency) are derived solely from owner observations. Other factors that may be included in placebo responses in veterinary studies include regression to the mean, investigator bias, client bias, the potential for a higher level of care during the study, and improved adherence to treatment with active medication that is being administered in addition to the placebo during the study (for details see [ 57 ] ). Furthermore, the placebo response can be because of effects of placebo administration on the animal, which is well documented in laboratory animals and may involve conditioned responses among others [ 55 ] . As a consequence, studies on new treatments in laboratory animals (or pets) should always include a "placebo" group receiving all manipulations (e.g., handling, injections, electrode implantation, seizure recording etc.) that are used for the new treatment. In addition to chronic epilepsy, naturally occurring canine status epilepticus (SE) has been proposed as a translational platform for evaluating investigational compounds for eventual use in human trials [ 34 ] and a controlled study on i.v. levetiracetam for treatment of SE in dogs has been published recently [ 23 ] .
One important caveat that has to be considered when using dogs for long-term studies on AEDs is that dogs, similar to rodents, eliminate many drugs, including most AEDs, much more rapidly than humans (Table 23 .1 ). Thus, when using AEDs such as phenytoin, carbamazepine or valproate with too low half-lifes for maintenance treatment in epileptic dogs, no suffi cient drug , 1935-1984 [ 24 ] ; a similar graph was initially shown by Lowenstein [ 35 ] . The graph on dogs illustrates data from a recent epidemiologic study on canine epilepsy [ 69 ] levels and, hence, no antiepileptic effects are obtained in this species [ 20 , 36 , 37 ] . The few AEDs with suffi ciently long half-lives for maintenance treatment include phenobarbital, primidone (because of its metabolism to phenobarbital), and potassium bromide, which is the reason why until recently only these old drugs were approved for treatment of canine epilepsy in the US or Europe. This situation has changed by the recent approval of imepitoin for treatment of dogs with newly diagnosed epilepsy (see below). Furthermore, several newer AEDs, including levetiracetam, felbamate, zonisamide, topiramate, gabapentin, and pregabalin are used as addon treatment in dogs with pharmacoresistant seizures [ 64 ] . It has been tried to overcome the problem of too rapid elimination of most AEDs by dogs by using sustained-release formulations; however, sustained-release preparations developed for use in humans are not suited for dogs because of the much higher gastrointestinal passage rate in dogs (~24 h) vs. humans (~65-100 h) [ 36 , 44 ] . Thus, AED formulations that exhibit retarded release of the drug in the gastrointestinal tract have to be adapted to the dog to overcome problems associated with too rapid drug elimination in this species. For phenytoin, a slow-release preparation has been developed for dogs, by which therapeutic plasma levels could be maintained despite the rapid elimination of this drug in dogs [ 18 ] , but, to our knowledge, no clinical experience with this preparation has been published. Vigabatrin has been evaluated for control of epilepsy in dogs, because its mechanism of action (irreversible inhibition of GABA degradation) allows an effective treatment which should be independent of species differences in drug elimination. Vigabatrin proved to be effective in epileptic dogs with phenobarbital-resistant seizures, but at least in part vigabatrin had to be withdrawn because of development of severe adverse effects, such as haemolytic anaemia [ 67 ] .
Löscher's group has used dogs as a translational model over the recent 25 years in the development of a new category of AEDs, i.e., drugs that act as partial agonists at the benzodiazepine (BZD) site of the GABA A receptor. Such drugs have the wide spectrum of antiepileptic activity against diverse types of seizures as the traditional full BZD agonists such as diazepam, clonazepam or clobazam, but are much better tolerated and lack the tolerance and abuse liability of the full agonists [ 22 , 41 ] . In our studies, we either used a canine seizure model, in which seizures are induced by i.v. infusion of pentylenetetrazole, or epileptic dogs. The fi rst partial BZD agonist that was characterized in dogs (and compared with full BZD agonists) was the β-carboline abecarnil, providing proof-of-concept that partial BZD agonists are advantageous for treatment of seizures compared to traditional, full-agonist BZDs [ 39 , 41 ] . More recently, the low-affi nity partial BZD agonist imepitoin, an imidazolin derivative, was evaluated in the dog seizure model and epileptic dogs and reported to provide effi cacious antiepileptic activity without the known disadvantages of full BZD agonists [ 45 , 51 ] . Based on several randomized controlled clinical trials in epileptic dogs, imepitoin was recently approved in Europe for treatment of canine epilepsy [ 13 , 51 ] . That imepitoin is an effective and safe AED in epileptic dogs indicates that low-affi nity partial BZD agonists may offer a new mechanistic category of useful AEDs.
Network Approaches for Development of Novel Treatments
Several of the models described in this review may be particularly interesting for evaluating a novel strategy of AED development, the network approach [ 3 , 26 , 50 ] . One of the dominant strategies in drug discovery is designing maximally selective ligands to act on individual drug targets [ 26 ] . However, many effective drugs act via modulation of multiple targets rather than single proteins. Furthermore, most epilepsies develop not from alterations of a single target but rather from complex alterations resulting in an epileptic network in the brain. The only existing cure of epilepsy is resective surgery in which the regional epileptic network or part of this network is removed. Thus, treatments focusing exclusively on a single protein or individual biochemical pathway may be less effective than treatments targeting different proteins or pathways involved in the network. The latter approach has been recently termed "network pharmacology" and relates to principles of systems biology [ 3 , 26 ] . The principle of network pharmacology is to develop combinations of existing drugs, which regulate activity via different targets within a biological network, for diseases that do not sufficiently respond to single drug treatment or for which no treatment exists. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets [ 26 ] . However, the rational design of polypharmacology faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties. The advances in zebrafi sh chemical screening technologies may allow rapid identifi cation of the most interesting drug combinations resulting from network approaches, followed by evaluating these combinations in chronic models of epilepsy. Some examples for interesting network approaches include combinations of glutamate receptor antagonists that target different glutamate receptor subtypes. We reported that extremely low doses of the NMDA (N-methyl-Daspartate ) receptor antagonist MK-801 (dizocilpine) markedly potentiated the anticonvulsant effect the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline) without increasing its adverse effects [ 42 ] . Similar over-additive effects were seen when NBQX was combined with the competitive NMDA antagonist CGP39551 (the carboxyethylester of DL-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid) or the low-affi nity, rapidly channel blocking NMDA receptor antagonist memantine [ 42 , 43 ] . We are currently evaluating combinations of clinically approved NMDA antagonists (ketamine, memantine) and the novel AMPA antagonist perampanel in models of diffi cult-to-treat seizures. Another interesting example is the combination of phenobarbital with the diuretic bumetanide, which is currently evaluated clinically following promising preclinical data [ 31 , 52 ] . The biologically plausible idea behind this combination is that a shift from inhibitory to excitatory GABA may be involved in diffi cult-to-treat neonatal and adult seizures [ 30 , 56 ] . GABA-mediated excitation has been observed when expression of the chloride importer NKCC1 is higher than expression of the chloride exporter KCC2; e.g., early during development and in the hippocampus of adults with temporal lobe epilepsy [ 30 , 56 ] . Bumetanide inhibits the neuronal chloride cotransporter NKCC1, thereby reverts the GABA shift and enables GABAmimetic drugs such as phenobarbital to potentiate inhibitory GABAergic transmission [ 52 ] . This recent work builds on an earlier demonstration from the Schwartzkroin laboratory that furosemide, another chloride cotransporter inhibitor, exhibits powerful anticonvulsant activity across a range of in vitro and in vivo seizure models [ 25 ] . Further examples for interesting network approaches include combined targeting of different infl ammatory pathways, which are involved in seizure generation [ 33 ] . These examples strongly indicate that combinatorial treatment strategies offer new options for epilepsy therapy.
Conclusions
Models for the discovery of drugs with antiepileptic activity have traditionally relied on a relatively small number of acute seizure models employed in otherwise healthy rodents. While useful in the discovery of most drugs currently available in the clinic, more resistant types of epilepsies including temporal lobe epilepsy patients who are unresponsive to available AEDs and catastrophic, often genetically-based, types of epilepsies seen in children necessitate alternative drug discovery strategies. Zebrafi sh, canine and novel rodent approaches are described here and offer several unique advantages over these traditional models. While these strategies, like any animal model approach also have their limitations, they offer hope that new classes of AEDs will be identifi ed in the coming years. Furthermore, animal models in which epilepsy develops after brain insults or gene mutations are essential in the search for novel antiepileptogenic treatments that prevent or modify the development of epilepsy in patients at risk [ 47 , 63 ] . Previously, this fi eld was dominated by studies in SE models in rats, although SE is only rarely a cause of symptomatic epilepsy [ 47 ] . Thus, models of more common causes of acquired epilepsy, such as traumatic brain injury, and models in which epilepsy develops after gene mutations should be used more extensively in research on antiepileptogenesis. We have started to use the zebrafi sh and canine approaches to identify molecular pathways that may be involved in the epileptogenic process and may offer new targets for antiepileptogenic treatments.
